The company confirmed Wednesday that the updated filing includes comprehensive analyses specifically requested by the Food and Drug Administration to bolster the initial application. With the submission now back in agency hands, management anticipates a standard six-month review cycle.
In section Market Quotes
Corcept Therapeutics Resubmits Relacorilant Application to FDA
Following a request for further efficacy data last December, Corcept Therapeutics has officially resubmitted its new drug application for relacorilant. The move marks a renewed attempt to secure regulatory approval for the treatment, which targets Cushing’s syndrome—a debilitating disorder driven by prolonged exposure to excess blood cortisol.
Chief Executive Officer Joseph Belanoff expressed optimism regarding the progress, noting that the firm is prepared to work closely with regulators to move the therapy toward market authorization. If approved, relacorilant would offer a new therapeutic path for patients struggling with the hormonal imbalances characteristic of the condition.
Comments (0)
No comments yet. Be the first!